Notwithstanding the COVID-19 pandemic challenges, Hutchison China MediTech (HCM) remains on track for potential approval and launches of two additional assets (surufatinib and savolitinib) in China in 2020/21. HCM is actively engaging with regulators (including the China NMPA and US FDA) with regards to trial initiations and NDA submissions as it continues on its trajectory to a global innovative oncology company. Furthermore, given the broader pipeline progression, it has a high level of vis
22 Apr 2020
Hutchison China MediTech - Fortune favours the brave
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Hutchison China MediTech - Fortune favours the brave
HUTCHMED (China) Limited (HCM:LON) | 266 4 0.6% | Mkt Cap: 2,322m
- Published:
22 Apr 2020 -
Author:
Dr Susie Jana -
Pages:
5
Notwithstanding the COVID-19 pandemic challenges, Hutchison China MediTech (HCM) remains on track for potential approval and launches of two additional assets (surufatinib and savolitinib) in China in 2020/21. HCM is actively engaging with regulators (including the China NMPA and US FDA) with regards to trial initiations and NDA submissions as it continues on its trajectory to a global innovative oncology company. Furthermore, given the broader pipeline progression, it has a high level of vis